U.S. Life Sciences Stock News

Estée Lauder Companies (EL) is back in the spotlight after unveiling Glimmer, a new prestige fragrance aimed at a new generation of consumers and featuring Hailee Steinfeld as the face of a global campaign. See our latest analysis for Estée Lauder Companies. Estée Lauder Companies’ Glimmer launch and recent board changes come as the stock shows short term momentum, with a 90 day share price return of 11.97%, but longer term total shareholder returns over one, three and five years still...

Happen stock edged up 1.1% to US$18.95 into the close, a modest move for a quarter that put earnings power firmly in the spotlight. Traders saw a routine beat. Long term investors saw something different. Diluted EPS hit about US$0.50 for Q2, with return on tangible common equity near 15.9%, and management raised full year EPS guidance to a higher range. The near term chart still shows a decline over the past month, which keeps shorter term holders cautious. The key question now is whether...

Levi Strauss (LEVI) is back in focus after TD Cowen downgraded the stock to Equal Weight due to valuation following a recent rally, just as the company pushes further into premium lifestyle categories. See our latest analysis for Levi Strauss. At a share price of US$25.46, Levi Strauss has seen a 90 day share price return of 16.31%, while the 1 year total shareholder return sits at 27.39%. This performance has attracted valuation concerns alongside its push into premium lifestyle...

Brinker International (EAT) has drawn fresh attention after recent Zacks research highlighted its rising earnings estimates and strong share performance over the past month relative to the retail restaurant industry. See our latest analysis for Brinker International. For context, Brinker International’s recent momentum has been strong, with a 30.83% year to date share price return and a very large 3 year total shareholder return around 7x, which points to building optimism around its earnings...

Trimble (TRMB) has drawn investor attention after recent share price swings, with the stock up 16.5% over the past week and 15% over the past month, despite weaker longer term returns. See our latest analysis for Trimble. The recent rally comes after a tougher spell, with the share price down 25.47% year to date and the 1 year total shareholder return declining 31.47%. The 3 year total shareholder return of 8.59% suggests longer term momentum has been more modest. If Trimble’s jump has you...

Wayfair (W) shares have been in focus after the company reported first quarter revenue growth of 7.4% year on year, ahead of analyst expectations, and a 5.2% Adjusted EBITDA margin, which marked its strongest first quarter profitability in five years. See our latest analysis for Wayfair. Wayfair's recent earnings release and the 11.5% 7 day share price return sit within a mixed picture. The stock has a 90 day share price return of 29%, while the year to date share price return is down 11.3%,...

ServiceNow (NOW) is back in focus after a mix of company specific and sector wide catalysts, including accelerating revenue growth, higher full year guidance, and renewed investor interest in enterprise software stocks. See our latest analysis for ServiceNow. ServiceNow shares have rebounded sharply in the short term, with a 1 month share price return of 12.49% and a 3 month gain of 24.45%. However, the year to date share price return is still down 24.98% and the 1 year total shareholder...

Polaris stock came into this earnings print after a soft stretch, with the shares down over the past month and giving up another 4.2% today to close at US$71.59. That move suggests investors saw a problem. The headline numbers tell a different story. Q2 2026 flipped back to profit with basic earnings per share of US$1.85 on revenue of US$2,039.6m, after a loss in Q1. Management also raised full year guidance, which puts the focus squarely on whether this profit rebuild is durable or just a...

Earlier this year, Ocular Therapeutix reported first-quarter results with revenue holding flat year over year and falling short of analyst expectations by 16.5%, prompting management to highlight ongoing cost control and pipeline priorities. Despite the weak quarter, CEO Pravin U. Dugel pointed to encouraging advancement of the AXPAXLI phase 3 trial in wet age-related macular degeneration, underscoring management’s focus on long-term retinal opportunities. Now we’ll examine how the flat...

In July 2026, the U.S. Air Force's Air Combat Command awarded Leidos Holdings a new intelligence, surveillance and reconnaissance support task order with a total potential value of about US$717 million over a possible five-year period, covering more than 35 locations across the United States and overseas. This award extends Leidos’ role as prime contractor on this mission since 2019 and underscores the company’s embedded position in complex, multi-domain defense intelligence support. Next,...

Marriott International stock has delivered a strong 5 year run, yet current valuation checks suggest the shares are trading at a premium to an intrinsic value estimate and to market based multiples. Marriott International has returned 179.9% over the past 5 years, which puts extra attention on whether the current share price still reflects a reasonable pay off for that performance. Recent expansion moves into all inclusive resorts and branded apartments may support long term cash flow...

In the second quarter of 2026, American Airlines Group Inc. reported record revenue of US$16,735 million but saw net income fall to US$71 million from US$599 million a year earlier, while also issuing guidance that third-quarter 2026 revenue would grow 16% to 19% year over year and unit revenue would improve versus the second quarter. Despite lowering its full-year earnings outlook amid sharply higher fuel costs, American Airlines highlighted growing premium and loyalty revenues and added...

Blackstone Mortgage Trust (BXMT) is back on investors’ radar after recent share price moves, with the stock closing at US$16.64. The company’s latest performance is drawing attention to its commercial real estate lending focus. See our latest analysis for Blackstone Mortgage Trust. Over the past few months, Blackstone Mortgage Trust’s share price return has trended lower, with the stock down 4.53% over 30 days and 12.79% over 90 days, while the 1-year total shareholder return declined 4.92%...

Shares of Baxter International (BAX) moved higher in the latest session after TD Cowen lifted its valuation outlook on the stock while keeping a neutral rating, drawing fresh attention to the healthcare supplier. See our latest analysis for Baxter International. The TD Cowen revision comes after a strong run in Baxter International's share price, with a 90 day share price return of 44.20% and a year to date share price return of 24.97%. However, the 1 year total shareholder return has...

Recent commentary around Brookfield Infrastructure Partners (NYSE:BIP) has focused on its exposure to power hungry AI data centers and other essential infrastructure, with upbeat sentiment building ahead of the partnership’s upcoming earnings report. See our latest analysis for Brookfield Infrastructure Partners. The recent run in Brookfield Infrastructure Partners’ share price, with a 30 day share price return of 14.56% and a year to date share price return of 22.24%, adds to a 1 year total...

Amgen stock has delivered an 88.5% total return over the past five years, and the latest Discounted Cash Flow (DCF) estimate currently points to the shares trading at a 43.0% discount to intrinsic value, while broader valuation checks paint a more mixed picture. Over five years, Amgen has returned 88.5%, which puts current investors in a strong position and raises the question of how much of the story is already reflected in the share price. Management confidence around a broad portfolio of...

AXT (AXTI) heads into its second quarter 2026 earnings report on July 30, with investor attention centered on AI related demand, a record indium phosphide backlog and recent manufacturing expansion. See our latest analysis for AXT. AXT’s share price has pulled back sharply in recent weeks, with a 1 day share price return of down 10.69% and a 30 day share price return of down 39.04%. However, the year to date share price return of 155.13% and a very large 1 year total shareholder return...

PBF Energy was recently highlighted as a leading low‑beta U.S. refiner, with strong refinery utilization helping it serve resilient fuel demand despite elevated oil input costs. This focus on PBF’s role in meeting steady U.S. demand while managing higher feedstock prices underscores how its refining operations may help buffer cost pressures. We’ll now examine how PBF’s positioning as a leading low‑beta refiner amid resilient U.S. demand may influence its investment narrative. Rare earth...

On July 14, 2026, C3.ai, Inc. reported that a U.S. federal court dismissed in full a putative securities class action lawsuit filed against the company and certain officers in August 2025, removing all asserted causes of action. This legal outcome lifts a significant source of uncertainty around potential litigation exposure and compliance concerns that had been hanging over C3.ai’s operations and governance. With the securities lawsuit dismissed, we’ll examine how reduced legal overhang...

FDA has approved Freenome's SimpleScreen blood-based colorectal cancer test for average-risk adults. Abbott Laboratories, NYSE:ABT, holds exclusive rights to commercialize SimpleScreen in the U.S. This agreement expands Abbott's colorectal cancer screening portfolio and strengthens its role in blood-based diagnostics. Abbott Laboratories, NYSE:ABT, is moving into a higher profile position in colorectal cancer screening through this new U.S. commercialization partnership for SimpleScreen...

Biohaven (BHVN) is back in focus after a federal jury found that Avilar Therapeutics and RA Capital Management willfully misappropriated trade secrets tied to its licensed MODA protein degradation platform, awarding damages to Biohaven and Yale University. See our latest analysis for Biohaven. Following the verdict, Biohaven's share price has eased in the very short term, with a 1-day share price return of 5.10% decline and a 7-day share price return of 11.22% decline. However, the 90-day...

Dolby Laboratories stock has had a tough run over the past few years, yet the valuation checks currently lean cheap and suggest the market may be pricing the business more pessimistically than those checks imply. Over the last 5 years, shareholders have seen the stock decline 43.1%, which points to a long stretch of weak returns that may already reflect a lot of caution. Future demand for Dolby Laboratories' audio and imaging technologies can support the case for the current price, while any...

The US Bureau of Economic Analysis is about to tweak how it measures the Fed’s preferred inflation gauge, the PCE index, and that could subtly shift how markets think about interest rates. A small downward adjustment to recent inflation readings may ease some pressure on future rate hikes, which often matters for growth oriented technology stocks with long term earnings stories. At the same time, debate around the timing and transparency of the change may keep volatility alive. This article...

Boeing stock jumped 4.8% to US$221.56 today, even as the headline print was another quarterly loss. The market cheered the cash story instead of the earnings line. Revenue for the second quarter came in at US$24.6b and free cash flow turned positive at US$631m, which matters far more for a heavily indebted manufacturer than a single quarter of earnings per share. Short term traders are reacting to relief. Long term investors will be weighing that fresh cash generation against a still heavy...